Cerus Corporation (CERS) is an American biotechnology company that specializes in the research, development, and commercialization of technologies in the field of blood transfusion safety. The company was established in 1991 and is currently headquartered in Concord, California. Cerus Corporation provides systems that are used globally for plasma, platelet, and red blood cell system needs in the blood transfusion industry, making the transfusion process safer and more efficient.
The flagship product of Cerus Corporation is the INTERCEPT Blood System. This system is specifically designed for the reduction of pathogens in platelets and plasma. The company also sells the INTERCEPT Blood System for red blood cells. This proprietary system uses a technology called pathogen inactivation, which can prevent the transmission of diseases through transfusions by deactivating viruses, bacteria, parasites, and other harmful organisms. Hence its major contribution to ensuring safety and preventing transfusion-transmitted infections during blood transfusions.
Cerus Corporation conducts a partnership program with blood centers, hospitals, and clinicians throughout the world to apply this technology widely and improve the standard of care in blood transfusion safety. It markets its products globally, with a presence in the United States, Europe, the Middle East, and other international locations. The company focuses on expanding its international presence in high-growth markets to further deliver its products to a broader range of global medical facilities.
In addition to product development, Cerus Corporation also devotes a significant portion of its operations to research and development activity. It collaborates with academic, industry, and government organizations to drive technological advancements in blood safety.
As an organization, Cerus Corporation balances both innovation and responsibility. Amid financial success, the company also holds a commitment to corporate social responsibility. It strives to adhere to ethical business practices while contributing to humanitarian goals. Cerus Corporation is not just in the business of providing safe blood products; it works to raise the standards of blood safety, pushing the boundaries of technology and knowledge to make significant advancements in healthcare globally. The innovation at Cerus Corporation is guided by one core principle: to create a better and safer world.
In conclusion, Cerus Corporation (CERS) stands as an innovator in the biotechnology industry, not just through its groundbreaking products but also through its commitment to health, safety, and corporate social responsibility. It continues to strive in delivering safe, effective solutions in the field of blood transfusion safety while also undertaking a broader role of impacting healthcare on a worldwide spectrum.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cerus (NASDAQ:CERS) stock recently crossed above its 200-day moving average, trading at $2.53 with a 200-day moving average of $2.48. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $5.25. The company met its quarterly EPS expectations and reported $63.3 million in revenue, while institutional investors own a significant portion of the company and insiders have recently sold shares.
Bank of New York Mellon Corp has acquired 559,834 shares of Cerus Corporation (NASDAQ:CERS) worth approximately $1.64 million in the second quarter, making it a new position for the institution. Cerus, a biomedical products company, reported Q2 revenues of $63.3 million and a -$0.01 EPS, aligning with analyst estimates. Despite mixed analyst sentiment and the company's unprofitability, institutional investors now own 78.37% of Cerus.
Wall Street Zen has upgraded Cerus (NASDAQ:CERS) from a "hold" to a "buy" rating, despite the broader analyst consensus remaining "Hold" with an average price target of $5.25. Cerus met analyst expectations with quarterly revenue of $63.3 million and an adjusted EPS of $(0.01), and analysts project a $(0.04) loss per share for the full fiscal year. The company's stock opened at $2.59, and institutional investors own 78.37% of shares, while recent insider sales were primarily for tax withholding obligations.
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ:CERS), sold 30,000 shares of company stock totaling $89,529 on August 17, 2026, as part of a pre-arranged trading plan. The sale occurred while Cerus shares were trading near $2.97, reflecting significant gains over the past year. Despite positive Q2 2026 financial results, including an earnings beat and raised revenue guidance, the company faced concerns regarding margin pressure and cash usage.
Assenagon Asset Management S.A. significantly reduced its stake in Cerus Corporation by 74.8% in the second quarter, selling 936,043 shares but still retaining 315,050 shares valued at approximately $920,000. Despite this reduction, institutional investors collectively own 78.37% of Cerus. The biotechnology company reported quarterly revenue of $63.3 million and adjusted EPS of $(0.01), meeting analyst expectations, with analysts projecting a full-year loss of about $0.04 per share.
Wasatch Advisors LP reduced its stake in Cerus Corporation by 35.9% in the second quarter, selling 1,897,237 shares but still retaining 3.38 million shares valued at approximately $9.9 million. Cerus reported quarterly revenue of $63.3 million and an adjusted loss of $0.01 per share, meeting analyst expectations. The company currently holds a "Hold" consensus rating from analysts with an average price target of $4.00, while insiders have sold shares primarily to cover tax obligations.